Sign in

    Christopher Boerner

    Chair of the Board and Chief Executive Officer at Bristol-Myers Squibb Co
    Board
    Since November 1, 2023
    Age
    54 years
    Education
    Holds a Ph.D. and MA in business administration from the Haas School of Business at the University of California, Berkeley, and a BA in economics and history from Washington University in St. Louis.
    Tenure
    Joined BMY in 2015 as President and Head of U.S. Commercial Markets, later serving as President and Head of International Markets, Executive Vice President with roles including Chief Commercialization Officer and Chief Operating Officer, before being appointed Chief Executive Officer in November 2023 and elevated to Chair of the Board in April 2024.

    Also at Bristol-Myers Squibb Co

    AL
    Adam Lenkowsky
    Executive Vice President, Chief Commercialization Officer
    AP
    Amanda Poole
    Executive Vice President, Chief People Officer
    BH
    Benjamin Hickey
    President, RayzeBio Organization

    About

    Christopher Boerner, Ph.D., is a seasoned leader currently serving as the Chair of the Board and Chief Executive Officer at Bristol-Myers Squibb, and he is 54 years old as of February 2025. His personal background is marked by a strong academic foundation and a broad spectrum of experience in the biotechnology and pharmaceutical industries.

    After joining BMY in 2015 as the President and Head of U.S. Commercial Markets, he quickly advanced through several pivotal roles, including President and Head of International Markets, and as Executive Vice President in capacities such as Chief Commercialization Officer and Chief Operating Officer. His strategic expertise and successful leadership trajectory culminated in his appointment as Chief Executive Officer on November 1, 2023, with his role further expanded when he became Chair of the Board in April 2024.

    With over two decades of experience, his career includes noteworthy tenures at Seattle Genetics, Inc. and Genentech, as well as advisory roles with McKinsey & Company. His comprehensive background in healthcare, sales and marketing, and financial and risk management has played a critical role in driving transformative strategies at BMY, reinforcing his reputation as a visionary leader in the biopharma sector.

    $BMY Performance Under Christopher Boerner

    Past Roles

    OrganizationRoleDate RangeDetails
    Bristol Myers Squibb Chief Executive Officer (prior to Chair) November 2023–April 2024 Held before becoming Chair of the Board
    Bristol Myers Squibb Executive Vice President, Chief Operating Officer April 2023–October 2023
    Bristol Myers Squibb Executive Vice President, Chief Commercialization Officer 2018–2023
    Bristol Myers Squibb President and Head of International Markets 2017–2018
    Bristol Myers Squibb President and Head of U.S. Commercial Markets 2015–2017
    Seattle Genetics, Inc. Leadership Roles 2010–2015 Held roles of increasing responsibility
    Genentech Marketing Leadership Roles 2002–2010 Served in marketing leadership roles
    McKinsey & Company Consultant for Global Pharmaceutical and Biotechnology Clients N/AWorked earlier in his career serving global pharmaceutical and biotechnology clients

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Annual Base Salary$1,256,921Annual 2023Actual salary earned in 2023
    Company Contributions to Savings Plans$303,786Annual 2023Contributions to qualified and non-qualified savings plans

    Performance Compensation

    Data from  FY 2023

    Annual Target Bonus Opportunity

    MetricValue/DetailsNotes
    Effective DateNovember 1, 2023Base salary increased effective this date
    Base Salary$1,500,000New base salary as of November 1, 2023
    Target Bonus150% of base salary (
    $2,250,000)Based on 150% of the revised base salary
    Threshold Payout$76,279Minimum performance level for bonus payout
    Target Payout$1,525,579Expected payout based on performance targets
    Maximum Payout$3,051,159Cap on bonus payout
    Performance MetricsAggregate In-Line & New Product Revenues and Operating IncomeTotal Revenues and EPS replaced by these metrics
    Evaluation PeriodCalendar 2023Performance measured over the year
    Payment ScheduleAnnual, cash-basedNo vesting schedule applies for the cash bonus

    Annual Incentive Award Payment (Cash & Equity)

    MetricValue/DetailsNotes
    Target Incentive Award$1,525,579Base target for incentive award
    Company Performance Factor97.83%Reflects performance on financial, pipeline, and ESG metrics
    Actual Cash Payout$1,567,098Final payout after performance adjustments

    Equity Incentive Plan Awards (included within long-term incentives):

    Long-Term Incentive Awards

    Performance Share Units (PSUs)

    MetricValue/DetailsNotes
    Grant DateMarch 10, 2023
    Grant Date Fair Value$64.18 per unitRepresents 97.7% of the grant date closing price
    Grant Date Stock Price$65.71
    Performance MetricsCumulative Operating Margin, In-Line & New Product Revenue, and 3-Year TSR CAGRWeightings: 25%, 40%, 35% respectively
    Payout Range0% to 200% of target unitsDepending on performance thresholds (e.g., 95%-100%-105% for Operating Margin)
    Vesting Schedule3-year cliff vestingVest on March 10, 2026 contingent on continuous employment and achievement of performance goals

    Market Share Units (MSUs)

    MetricValue/DetailsNotes
    Grant DateMarch 10, 2023
    Grant Date Fair Value$58.15 per unitRepresents 88.50% of grant date stock price
    Grant Date Stock Price$65.71
    Performance MetricRatio of 10-day average closing price (measurement vs. grant date)Minimum payout factor is 80%; maximum is 225%
    Vesting Schedule4 equal annual installmentsVest on anniversaries of the grant date from 2024 to 2027

    Additional Long-Term Award (Post-Promotion to CEO)

    MetricValue/DetailsNotes
    Effective DateNovember 1, 2023Award upon promotion to CEO
    Award Value$1,600,000 totalSplit into PSUs and MSUs
    PSUs Component$664,204 totalVest on November 1, 2026
    MSUs Component$503,135 totalVest in four equal installments from 2024 to 2027

    These components collectively form the performance compensation for 2023. They include both cash-based bonus mechanisms and share-based awards, each with specific performance metrics, thresholds, targets, and vesting schedules as detailed above.